Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

businesswire.com
CORT The article announces Corcept Therapeutics' upcoming third quarter financial results and corporate update, including a conference call. It provides details on how to access the call and a brief overview of the company's focus on cortisol modulation and its approved medications.

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call REDWOOD CITY, Calif.--( BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller.

Additionally, a listen-only webcast will be available by clicking here.

A replay of the call will be available on the Investors / Events tab of Corcept.com.

About Corcept Therapeutics

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders. We have discovered more than 1,000 proprietary selective glucocorticoid receptor antagonists. Our development activities include advanced clinical trials in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. In 2012, we introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous Cushing’s syndrome. In March 2026, we introduced Lifyorli ® as a treatment for patients with platinum-resistant ovarian cancer. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist. We are headquartered in Redwood City, California. For more information, visit Corcept.com.